PRRT2 and cancer: The PLC, PI3K, and MAPK-ERK signaling pathways, activate downstream kinases, such as PKC and PKA, which phosphorylate TRPV1 and TRPA1 channels and promote channel sensitization and reduction of their activation threshold, potentially contributing to the pain sensation experienced by cancer patients.